Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narsoplimab in Paediatric HSCT-TMA
2023-509710-11-00Phase 2Authorised
- Sponsor
- Omeros Corporation
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of narsoplimab in thrombotic microangiopathies (TMA), sponsored by Omeros Corporation. Primary endpoint: 100-day survival rate from date of HSCT-TMA diagnosis. Planned start Jun 2024; status: authorised.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2023-509710-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509710-11-00.